Literature DB >> 15250925

National surveillance of dialysis-associated diseases in the United States, 2001.

Jerome I Tokars1, Lyn Finelli, Miriam J Alter, Matthew J Arduino.   

Abstract

In December 2001, all U.S. chronic hemodialysis (HD) centers were surveyed regarding selected patient care practices and dialysis-associated diseases. The results were compared with similar surveys conducted in previous years. During 1997-2001, the percentage of patients vaccinated against hepatitis B virus (HBV) infection increased from 47% to 60% and the percentage of staff vaccinated increased from 87% to 89%. In 2001, an estimated 65% of patients had been vaccinated for influenza and 26% for pneumococcal pneumonia. In 2001, routine testing for antibody to hepatitis C virus (anti-HCV) was performed on staff at 42% of centers and on patients at 62% of centers; anti-HCV was found in 1.5% of staff and 8.6% of patients. In 2001, the incidence of HBV infection was higher among patients in centers where injectable medications were prepared at the dialysis station, and both HCV prevalence and incidence were higher among patients in centers where injectable medications were prepared at the dialysis station compared to a dedicated medication room. During 1995-2001, the percentage of patients who received dialysis through central catheters increased from 13% to 25%; this trend is worrisome, as infections and antimicrobial use are higher among patients receiving dialysis through catheters. However, during the same period, the percentage of patients receiving dialysis through fistulas increased from 22% to 30%. In 2001, 25% of catheters were used for new patients awaiting an arteriovenous (AV) access, 28% for established patients with a failed access awaiting new AV access, 40% as an access of last resort, and 6% for other reasons, including patient preference. The percentage of centers reporting one or more patients infected or colonized with vancomycin-resistant enterococcus (VRE) increased from 12% in 1995 to 31% in 2001.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15250925     DOI: 10.1111/j.0894-0959.2004.17339.x

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  12 in total

1.  Infections in hemodialysis: a concise review. Part II: blood transmitted viral infections.

Authors:  T Eleftheriadis; V Liakopoulos; K Leivaditis; G Antoniadi; I Stefanidis
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

2.  Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis.

Authors:  Jenny Sauk; Donald M Jensen; Smruti R Mohanty; Nancy Reau; K Gautham Reddy; Helen S Te
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-07

3.  Mechanical integrity of hemodialysis catheters after exposure to a novel catheter lock solution.

Authors:  Saima Aslam; Rabih O Darouiche
Journal:  Infect Control Hosp Epidemiol       Date:  2010-11       Impact factor: 3.254

4.  A review of evolving dialysis catheter technologies.

Authors:  Martha-Grace Knuttinen; Sonia Bobra; Julian Hardman; Ron C Gaba; James T Bui; Charles A Owens
Journal:  Semin Intervent Radiol       Date:  2009-06       Impact factor: 1.513

5.  Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.

Authors:  Chika Nishida; Hirofumi Uto; Makoto Oketani; Koki Tokunaga; Tsuyoshi Nosaki; Mayumi Fukumoto; Manei Oku; Atsushi Sogabe; Akihiro Moriuchi; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-11-05       Impact factor: 7.527

6.  A cost-identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients.

Authors:  Ma Somsouk; Deston E Langfield; John M Inadomi; Hal F Yee
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

7.  Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients.

Authors:  Mohammad H Ghadiani; Shahin Besharati; Nouraddin Mousavinasab; Mojgan Jalalzadeh
Journal:  J Res Med Sci       Date:  2012-06       Impact factor: 1.852

8.  Hepatitis B and C in dialysis units in Kosova.

Authors:  Skender Telaku; Hajrullah Fejza; Ymer Elezi; Teuta Bicaj
Journal:  Virol J       Date:  2009-06-04       Impact factor: 4.099

9.  Diagnostic Performance of an Immunoassay for Simultaneous Detection of Hcv Core Antigen and Antibodies among Haemodialysis Patients.

Authors:  Wafaa M El-Emshaty; Douaa Raafat; Doaa M Elghannam; Niveen Saudy; Ehab E Eltoraby; Abd Elhameed A Metwalli
Journal:  Braz J Microbiol       Date:  2011-01       Impact factor: 2.476

10.  Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients.

Authors:  Masaki Ohsawa; Karen Kato; Kazuyoshi Itai; Kozo Tanno; Yosuke Fujishima; Ryuichiro Konda; Akira Okayama; Koichi Abe; Kazuyuki Suzuki; Motoyuki Nakamura; Toshiyuki Onoda; Kazuko Kawamura; Kiyomi Sakata; Takashi Akiba; Tomoaki Fujioka
Journal:  J Epidemiol       Date:  2009-10-31       Impact factor: 3.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.